Literature DB >> 33578793

Circulating Cell-Free DNA in Breast Cancer: Searching for Hidden Information towards Precision Medicine.

Maria Panagopoulou1, Manel Esteller2,3,4,5, Ekaterini Chatzaki1,6.   

Abstract

Breast cancer (BC) is a leading cause of death between women. Mortality is significantly raised due to drug resistance and metastasis, while personalized treatment options are obstructed by the limitations of conventional biopsy follow-up. Lately, research is focusing on circulating biomarkers as minimally invasive choices for diagnosis, prognosis and treatment monitoring. Circulating cell-free DNA (ccfDNA) is a promising liquid biopsy biomaterial of great potential as it is thought to mirror the tumor's lifespan; however, its clinical exploitation is burdened mainly by gaps in knowledge of its biology and specific characteristics. The current review aims to gather latest findings about the nature of ccfDNA and its multiple molecular and biological characteristics in breast cancer, covering basic and translational research and giving insights about its validity in a clinical setting.

Entities:  

Keywords:  biomarker; breast cancer; circulating cell-free DNA; liquid biopsy; monitoring; prognosis

Year:  2021        PMID: 33578793      PMCID: PMC7916622          DOI: 10.3390/cancers13040728

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  202 in total

Review 1.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

Authors:  Massimo Cristofanilli
Journal:  Semin Oncol       Date:  2006-06       Impact factor: 4.929

2.  Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies.

Authors:  Jörg Ellinger; David C Müller; Stefan C Müller; Stefan Hauser; Lukas C Heukamp; Alexander von Ruecker; Patrick J Bastian; Gisela Walgenbach-Brunagel
Journal:  Urol Oncol       Date:  2010-09-26       Impact factor: 3.498

3.  DNA methylation of circulating DNA: a marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients.

Authors:  Gayatri Sharma; Sameer Mirza; Rajinder Parshad; Siddartha Datta Gupta; Ranju Ralhan
Journal:  Tumour Biol       Date:  2012-06-29

4.  Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients.

Authors:  Thomas E Liggett; Anatoliy A Melnikov; Jeffrey R Marks; Victor V Levenson
Journal:  Int J Cancer       Date:  2010-04-05       Impact factor: 7.396

5.  Circulating cell-free DNA: a promising marker of regional lymphonode metastasis in breast cancer patients.

Authors:  M Agostini; M V Enzo; C Bedin; V Belardinelli; E Goldin; P Del Bianco; E Maschietto; E D'Angelo; Leo Izzi; A Saccani; G Zavagno; D Nitti
Journal:  Cancer Biomark       Date:  2012       Impact factor: 4.388

6.  Mitochondrial copy number and risk of breast cancer: a pilot study.

Authors:  Jie Shen; Mary Platek; Amjad Mahasneh; Christine B Ambrosone; Hua Zhao
Journal:  Mitochondrion       Date:  2009-09-27       Impact factor: 4.160

7.  Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.

Authors:  Clara Chen; Rahul Dhanda; Wan-Yu Tseng; Michael Forsyth; Debra A Patt
Journal:  J Oncol Pract       Date:  2013-02-12       Impact factor: 3.840

8.  Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer.

Authors:  Magdalini Kioulafa; Ioanna Balkouranidou; Georgia Sotiropoulou; Loukas Kaklamanis; Dimitris Mavroudis; Vassilis Georgoulias; Evi S Lianidou
Journal:  Int J Cancer       Date:  2009-12-15       Impact factor: 7.396

9.  Circulating tumor cells versus tumor-derived cell-free DNA: rivals or partners in cancer care in the era of single-cell analysis?

Authors:  Evelyn Kidess; Stefanie S Jeffrey
Journal:  Genome Med       Date:  2013-08-13       Impact factor: 11.117

10.  Diagnostic Value of Concentration of Circulating Cell-Free DNA in Breast Cancer: A Meta-Analysis.

Authors:  Dandan Yu; Yan Tong; Xinnian Guo; Lingfang Feng; Zhaoqiang Jiang; Shibo Ying; Junlin Jia; Yuan Fang; Min Yu; Hailing Xia; Li Shi; Jianlin Lou
Journal:  Front Oncol       Date:  2019-03-01       Impact factor: 6.244

View more
  7 in total

1.  Just Add Data: automated predictive modeling for knowledge discovery and feature selection.

Authors:  Ioannis Tsamardinos; Paulos Charonyktakis; Georgios Papoutsoglou; Giorgos Borboudakis; Kleanthi Lakiotaki; Jean Claude Zenklusen; Hartmut Juhl; Ekaterini Chatzaki; Vincenzo Lagani
Journal:  NPJ Precis Oncol       Date:  2022-06-16

Review 2.  Current and Developing Liquid Biopsy Techniques for Breast Cancer.

Authors:  Hsing-Ju Wu; Pei-Yi Chu
Journal:  Cancers (Basel)       Date:  2022-04-19       Impact factor: 6.575

3.  ENPP2 Methylation in Health and Cancer.

Authors:  Maria Panagopoulou; Dionysios Fanidis; Vassilis Aidinis; Ekaterini Chatzaki
Journal:  Int J Mol Sci       Date:  2021-11-04       Impact factor: 5.923

Review 4.  Computational challenges in detection of cancer using cell-free DNA methylation.

Authors:  Madhu Sharma; Rohit Kumar Verma; Sunil Kumar; Vibhor Kumar
Journal:  Comput Struct Biotechnol J       Date:  2021-12-07       Impact factor: 7.271

5.  ENPP2 Promoter Methylation Correlates with Decreased Gene Expression in Breast Cancer: Implementation as a Liquid Biopsy Biomarker.

Authors:  Maria Panagopoulou; Andrianna Drosouni; Dionysiοs Fanidis; Makrina Karaglani; Ioanna Balgkouranidou; Nikolaos Xenidis; Vassilis Aidinis; Ekaterini Chatzaki
Journal:  Int J Mol Sci       Date:  2022-03-28       Impact factor: 5.923

Review 6.  Diagnostic and Therapeutic Potential of Circulating-Free DNA and Cell-Free RNA in Cancer Management.

Authors:  Sadia Hassan; Adeeb Shehzad; Shahid Ali Khan; Waheed Miran; Salman Khan; Young-Sup Lee
Journal:  Biomedicines       Date:  2022-08-22

7.  Size and Methylation Index of Cell-Free and Cell-Surface-Bound DNA in Blood of Breast Cancer Patients in the Contest of Liquid Biopsy.

Authors:  Svetlana Tamkovich; Alexey Tupikin; Anton Kozyakov; Pavel Laktionov
Journal:  Int J Mol Sci       Date:  2022-08-10       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.